Chemotherapy for metastatic breast cancer —When is enough enough?
- 1 November 1997
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (13) , 2147-2148
- https://doi.org/10.1016/s0959-8049(97)00257-8
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breastEuropean Journal Of Cancer, 1997
- Statistics notes: Absence of evidence is not evidence of absenceBMJ, 1995
- Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 monthsEuropean Journal Of Cancer, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Duration of chemotherapy in advanced breast carcinomaThe Lancet, 1990
- Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancerThe Lancet, 1990
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978